At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 26 enrolled
Drug / intervention
recombinant interferon alfa +1 morebiological
Likely dose
Not stated in record
Key inclusion· 7
- ✓Histologically confirmed metastatic renal cell carcinoma
- ✓Bidimensionally measurable disease
- ✓Age 18 years or older
- ✓Karnofsky performance status 60-100%
Key exclusion· 11
- ✕Active brain metastases
- ✕Prior retinoid therapy
- ✕Concurrent steroid use
- ✕Clinically significant hepatic disease, including autoimmune hepatitis
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Trial of Atragen and Interferon Alfa-2b in Patients With Advanced Renal Cell Carcinoma
In Brief
A Phase 2 clinical trial evaluating recombinant interferon alfa and tretinoin liposome for Kidney Cancer. Completed, enrolled 26 participants across 2 sites.
Detailed Summary
RATIONALE: Tretinoin may help kidney cancer cells develop into normal cells. Interferon alfa may interfere with the growth of cancer cells. PURPOSE: Phase II trial to study the effectiveness of liposomal tretinoin plus interferon alfa in treating patients who have metastatic kidney cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsKidney Cancer
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
19992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJan 1999
First PostedJan 2003
Primary CompletionMay 2008
TodayJul 2026
First PostedJan 27, 2003
Enrollment StartJan 1, 1999
Primary CompletionMay 1, 2008
TodayJul 2, 2026
Enrollment to primary: 9.3 yearsPosted 23.4 years ago
Interventions
recombinant interferon alfabiological
tretinoin liposomedrug